Real-World Effectiveness and Cost-Effectiveness of Ceftazidime–Avibactam versus Colistin–Meropenem for ICU-Acquired MDR Gram-Negative Infections in Liver Transplant Recipients
In a retrospective cohort study of 190 adult liver transplant recipients with ICU-acquired multidrug-resistant Gram-negative infections, ceftazidime–avibactam demonstrated superior clinical response, microbiological eradication, and sepsis-related mortality reduction compared to colistin–meropenem, while also proving to be a cost-effective treatment option despite higher acquisition costs.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine you are a mechanic trying to fix a very expensive, custom-built car that has just been rebuilt from scratch. This car is a liver transplant, and the patient is the owner. The problem? The car's engine is being attacked by a gang of tiny, invisible saboteurs called bacteria. But these aren't ordinary saboteurs; they are "super-bugs" that have learned to ignore the standard tools mechanics usually use to stop them. In the world of medicine, these are called multidrug-resistant (MDR) bacteria. They are like lock-pickers who have figured out how to open every standard lock, leaving doctors with very few weapons left in their arsenal.
For a long time, doctors had to use a "heavy artillery" weapon called colistin to fight these super-bugs. Think of colistin as a sledgehammer: it's powerful enough to smash the bacteria, but it's also clumsy and can accidentally crack the car's other parts (like the kidneys) while doing the job. Recently, a newer, more precise tool called ceftazidime–avibactam (or CAZ/AVI for short) has arrived. It's like a high-tech, laser-guided wrench that targets the bacteria specifically without smashing everything else. But here's the big question: Is this fancy new tool actually better at saving the car, or is it just a more expensive toy that doesn't work any better? And if it does work better, is it worth the extra price tag? This is the mystery a team of researchers set out to solve by looking at real-life stories from a hospital.
The Great Battle in the ICU
In this study, researchers at a major liver transplant center in Turkey looked back at the medical records of 190 adult patients who had received a new liver and then got sick with these super-bug infections while in the Intensive Care Unit (ICU). It was a showdown between two treatment teams. One group of 100 patients was treated with the new, high-tech CAZ/AVI weapon. The other group of 90 patients was treated with the old-school "sledgehammer" combination of colistin and meropenem.
The researchers wanted to see who came out on top. They checked three main things: Did the infection go away? Did the patient get better? And did the patient survive the infection?
The results were pretty clear-cut. The team using the new CAZ/AVI tool won the day. About 87.5% of the patients treated with CAZ/AVI got a full "clinical response," meaning their infection signs disappeared and they didn't need to switch to a different drug. In contrast, only about 57.6% of the patients on the colistin team saw the same success. It was like the laser-guided wrench actually fixed the engine, while the sledgehammer left a lot of the problems unsolved.
Even more impressive was the "microbiological eradication" rate. This is a fancy way of saying, "Did we completely wipe out the bacteria?" With CAZ/AVI, the bacteria were gone in 95.8% of cases. With the colistin mix, they were only gone in 72.9% of cases. The new tool was just better at cleaning up the mess.
The most dramatic difference, however, was in who survived the infection. The study found that sepsis-related mortality (death caused specifically by the infection) was much lower in the CAZ/AVI group. Only 11.1% of those patients died from the infection, compared to a staggering 42.4% in the colistin group. That's a huge gap. It suggests that using the right weapon early on can mean the difference between life and death when fighting these super-bugs. Interestingly, when looking at all causes of death within 30 days (including things unrelated to the infection, like surgical complications), the two groups were about the same. This tells us that while the new drug was amazing at killing the bacteria and stopping the infection, the overall survival of these very sick patients is still influenced by many other tough factors.
The Price Tag Question
Now, you might be thinking, "If the new tool is so much better, does it cost a fortune?" The answer is yes, but with a twist. The researchers did the math on the cost of the drugs themselves. The CAZ/AVI treatment was significantly more expensive to buy upfront. The average cost for the colistin group was about 5,747.57 Turkish Lira (TL), while the CAZ/AVI group cost about 22,080.21 TL. That's a big difference in the price of the medicine bottle.
However, the researchers didn't just look at the price of the bottle; they looked at the "value" of the cure. They used a special calculation called the "Incremental Cost-Effectiveness Ratio" (ICER) to figure out how much extra money was spent to get one extra successful cure. They found that for every additional patient who got better with CAZ/AVI, the hospital spent an extra 54,442.13 TL.
To understand if this is a "good deal," the researchers ran thousands of computer simulations (called bootstrap resampling) to see how the numbers might wiggle. They found that if the hospital is willing to pay around 50,000 to 60,000 TL for a successful cure, the new drug becomes a very good investment. As the willingness to pay goes up to 100,000 TL, the chance that CAZ/AVI is the better economic choice jumps to nearly 100%.
The Bottom Line
So, what does this all mean? The study suggests that for liver transplant patients fighting these tough, super-resistant infections in the ICU, the new CAZ/AVI drug is a much more effective weapon than the old colistin combination. It kills the bacteria better, helps more patients recover, and saves more lives from sepsis. Even though the drug itself costs more to buy, the researchers argue that the better results make it a smart financial choice for the hospital in the long run, because it prevents the infection from dragging on and causing more trouble.
The authors are careful to say that this is based on looking back at past records from one specific hospital, so it's not a final, unchangeable law of the universe. But the evidence they found is strong: in this high-stakes battle for liver transplant patients, the new, precise tool seems to be winning the war against the super-bugs.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.